Overview of Type 2 Diabetes in India
Public Health Challenge
Type 2 Diabetes (T2D) poses a significant public health challenge, with India currently ranking second globally in its prevalence. The coexistence of diabetes, hypertension, and dyslipidemia contributes to accelerated atherosclerosis and endothelial dysfunction, which in turn leads to microvascular and macrovascular complications associated with cardiovascular diseases (CVDs). Clinicians face the critical challenge of identifying comprehensive therapeutic options that can effectively manage glucose levels while also providing cardiovascular and renal protection.
Rationale for Dapagliflozin and Sitagliptin-Based FDC Therapies
Targeting the Gluco-Cardio-Renal Perspective
An ideal glucose-lowering combination therapy should utilize complementary mechanisms to address various pathophysiological pathways across all stages of the disease. It should prioritize patient tolerance and minimize the risks of hypoglycemia or weight gain, while also enhancing convenience through single-pill, once-daily dosing.
Dapagliflozin, an SGLT2 inhibitor, facilitates osmotic diuresis and natriuresis, leading to reduced preload and afterload, improved myocardial metabolism, and enhanced hemodynamic stability. Meanwhile, Sitagliptin, a DPP-4 inhibitor, increases incretin activity (GLP-1 and GIP), which helps lower postprandial glucose levels, preserve β-cell function, and maintain a weight-neutral profile, ensuring lasting glucose control.
Beyond just glucose management, dapagliflozin aids in weight reduction, lowers blood pressure, and provides cardio-renal protection, addressing the comprehensive needs of Indian patients with T2D. The fixed-dose combination (FDC) of dapagliflozin and sitagliptin targets six out of the eight components of the ominous octet, addressing critical pathophysiological defects in T2DM and associated oxidative stress. This FDC further reduces pill burden, enhances tolerability, and improves cost-effectiveness while effectively controlling postprandial glucose levels.
Clinical Evidence on Cardio-Renal and Metabolic Outcomes
Cardiovascular Benefits
Cardiovascular issues remain a leading cause of disability and premature mortality among individuals with diabetes. Those with T2D face a 1.5 to 2 times higher risk of CVD compared to non-diabetics. In the DECLARE–TIMI 58 trial, involving 17,160 participants over a median follow-up of 4.2 years, dapagliflozin significantly decreased the risk of cardiovascular death or hospitalization for heart failure by 17%, primarily driven by a 27% reduction in heart failure hospitalizations. Dapagliflozin also demonstrated noninferiority in terms of major adverse cardiovascular events (MACE).
Sitagliptin, in patients with type 2 diabetes, showed no increase in cardiovascular risk. In direct comparisons, it exhibited a 100% lower rate of cardiovascular events compared to sulphonylureas. Both medications have established cardiovascular safety profiles, making them suitable for dual therapy in patients at risk for cardiovascular events, including heart failure.
Renal Benefits
Chronic kidney disease (CKD) affects nearly 40% of individuals with diabetes, and the lifetime risk of developing CKD in T2D patients can reach 54%. Consequently, renal protection is a crucial aspect of comprehensive diabetes management. In the DAPA-CKD trial, dapagliflozin significantly reduced the risk of a ≥50% decline in eGFR, end-stage kidney disease, or renal death by 44% and lowered the risk of cardiovascular death or heart failure hospitalization by 29%.
Sitagliptin has also shown renal protective effects by reducing high-glucose-induced oxidative stress and inflammation in glomerular endothelial cells. In a three-month clinical study involving 84 T2DM patients, sitagliptin decreased the albumin-creatinine ratio by 20.9 mg/g and improved eGFR significantly. The reduction in ACR was more pronounced in macroalbuminuric patients, highlighting sitagliptin’s potential in preventing diabetic kidney disease.
Metabolic Benefits: An Indian Experience
In a real-world, multicenter study involving 328 Indian T2DM patients, the combination of dapagliflozin and sitagliptin led to a notable reduction in HbA1c by 1.05% over 12 weeks. Fasting plasma glucose (FPG) also significantly decreased, as did postprandial blood glucose (PPBG) levels. Additionally, the therapy resulted in a reduction of LDL cholesterol and systolic blood pressure, underscoring its comprehensive metabolic benefits for patients.